Bell Potter Healthcare Conference 2020 Live-stream

Day 1 Schedule: Wednesday, 25 November 2020

8:00AM

WELCOME

James Unger, Head of Corporate Finance

MID CAP PHARMA

8:05AM

EXPERIENCE ON COVID-19 TO DATE

Mesoblast (MSB)
Silviu Itescu, Chief Executive Officer
Dr Fred Grossman, Chief Medical Officer

8:30AM

WET AGE-RELATED MACULAR DEGENERATION – WHAT’S IN THE PIPELINE?

Opthea (OPT)
Megan Baldwin, Managing Director & Chief Executive Officer

8:55AM

ZILUSOL COMMERCIALISATION UPDATE

Paradigm Biopharmaceuticals (PAR)
Paul Rennie, Chief Executive Officer

MID CAP HEALTHCARE

9:20AM

LOCAL AND GLOBAL EXPANSION PLANS

AFT Pharmaceuticals (AFP)
Hartley Atkinson, Chief Executive Officer
Malcolm Tubby, Chief Financial Officer

9:45AM

DELIVERING IMPROVED OUTCOMES – FOR COVID-19 AND BEYOND

Starpharma Holdings (SPL)
Jackie Fairley
Chief Executive Officer

10:10AM

EMVISION’S PILOT CLINICAL TRIAL FOR ITS BREAKTHROUGH PORTABLE BRAIN SCANNER

EMvision Medical Devices (EMV)
Dr Ron Weinberger, Managing Director
Scott Kirkland, Executive Director

COVID-19

10:45AM

THE GLOBAL IMPACT OF COVID-19 ON TELEHEALTH AND MENTAL HEALTH

Doctor Care Anywhere (DOC)
Bayju Thakar, Chief Executive Officer
Kate Bunyan,  Chief Medical Officer

Total Brain (TTB)
Louis Gagnon, Chief Executive Officer & Managing Director

11:15AM

THE IMPACT OF COVID-19 ON THE HOSPITAL SYSTEM

Oneview Healthcare (ONE)
James Fitter, Chief Executive Officer

Royal Rehabilitation Group
Matthew MacKay, Chief Executive Officer

PainChek (PCK)
Philip Daffas, Chief Executive Officer
John Murray, Non-Executive Director

11:45AM

HUNT FOR THE COVID-19 VACCINE

Bioshares
David Blake, Editor/Analyst & Co-founder of Bioshares

12:15PM

AUSTRALIA’S PUBLIC HEALTH RESPONSE TO THE COVID-19 PANDEMIC, PRE AND POST VACCINE IMPLEMENTATION

Dr. Rob Grenfell, Director CSIRO Health & Biosecurity
Professor Jodie McVernon, Professor and Director of Epidemiology

WOUND

12:40PM

1Q21 COMPANY UPDATE

Avita Therapeutics (AVH)
Mike Perry, Chief Executive Officer

1:05PM

BEYOND JUST BURNS – A VIRTUAL TOUR OF THE NEW PRODUCT MANUFACTURING FACILITY

Polynovo (PNV)
Paul Brennan, Chief Executive Officer
Jan-Marcel Gielen, Chief Financial Officer

1:30PM

CELGRO: RETURNING FUNCTION TO PARALYSED LIMBS

Orthocell (OCC)
Paul Anderson, Managing Director & Chief Executive Officer

1:55PM

A DEEP DIVE INTO THE BATTLE AGAINST BIOFILM

Next Science (NXS)
Judith Mitchell, Managing Director
Dr. Thorsten M. Seyler, MD & PhD

2:20PM

CLINICAL UPDATES AND INSIGHTS: A DISCUSSION WITH TELA BIO’S CHIEF MEDICAL OFFICER

Aroa Biosurgery (ARX)
Brian Ward, Chief Executive Officer
Dr Maarten Persanaire, TELA Bio’s Chief Medical Officer

2:50PM

PANEL DISCUSSION: TRENDS IN ADVANCED WOUND CARE

Aroa Biosurgery (ARX)
Brian Ward, Chief Executive Officer
James Agnew,  Chief Financial Officer

Polynovo (PNV)
Paul Brennan, Chief Executive Officer
Jan-Marcel Gielen, Chief Financial Officer

3:50PM

WRAP UP

James Unger, Head of Corporate Finance

Day 2 Schedule: Thursday, 26 November 2020

8:00AM

WELCOME

Anton Whitehead, Director of Equity Capital Markets

IMAGING SOFTWARE

8:05AM

VISAGE AI ACCELERATOR- A PLATFORM APPROACH TO AI IN RADIOLOGY

Pro Medicus (PME)
Dr Sam Hupert,  Chief Executive Officer

8:30AM

RESILIENCE AND CASE STUDIES

Volpara Heatlh Technologies (VHT)
Ralph Highnam,  Chief Executive Officer

8:55AM

COMMERCIALISATION OF XV TECHNOLOGY

4D Medical (4DX)
Andreas Fouras,  Chief Executive Officer

9:20AM

COMMERICALISATION UPDATE

Mach 7 Technologies (M7T)
Mike Lampron, Chief Executive Officer
Jenni Pilcher,  Chief Financial Officer

SMALL CAP PHARMACEUTICALS/ DIAGNOSTICS

9:55AM

DEPTH IN PRODUCTS AND PHARMA PARTNERSHIPS

Immutep (IMM)
Marc Voigt, Chief Executive Officer

10:15AM

UPDATE FROM GENETIC SIGNATURES SALES DIRECTORS

Genetic Signatures (GSS)
John Melki, Chief Executive Officer
Jackson Jones, Director of Global Sales and Marketing

10:35AM

LIVE DEMO OF EASY TO USE, AWARD WINNING RAPID TESTS FOR COVID-19 AND OTHERS

Atomo Diagnostics (AT1)
John Kelly, Chief Executive Officer
Will Souter, Chief Financial Officer

10:55AM

US COMMERICALISATION UPDATE

Cyclopharm (CYC)
James McBrayer, Chief Executive Officer

ONCOLOGY AND IMMUNO ONCOLOGY

11:15AM

IMUGENE PROGRAM UPDATE

Imugene (IMU)
Leslie Chong, Chief Executive Officer

11:35AM

COMMERICALISATION UPDATE

Oncosil Medical (OSL)
Daniel Kenny, Chief Executive Officer

11:55AM

TRANSITIONING TO A PIVOTAL STUDY

Kazia Therapeutics (KZA)
James Garner, Chief Executive Officer

12:15PM

IDIOPATHIC INTRACRANIAL HYPERTENSION (IIH) – A CLINICIAN’S PERSPECTIVE ON THIS RAPIDLY GROWING AND COSTLY DISORDER

Invex Therapeutics (IXC)
Tom Duthy, Executive Director

MID CAP DEVICES

12:55PM

PENTHROX: UNLOCKING OUR POTENTIAL IN EUROPE

Medical Developments International (MVP)
Brent MacGregor, Chief Executive Officer

1:20PM

BUSINESS UPDATE

Nanosonics (NAN)
Michael Kavanagh, Chief Executive Officer
McGregor Grant, Chief Financial Officer

1:45PM

PROCEDURE DEMONSTRATION OF IMRICOR’S NOVEL MRI COMPATIBLE CATHETERS

Imricor Medical Systems (IMR)
Steve Wedan, Chief Executive Officer

2:10PM

FOCUS ON ONGOING SALES PROGRESS AND DEMAND, IMPACT OF NEW FACILITY AND CLARITY ON GUIDANCE

Cleanspace (CSX)
Dr Alex Birrell, Chief Executive Officer
Elizabeth Harvey, Chief Financial Officer

2:35PM

TARGETING RADIOPHARMACEUTICALS: FOCUS ON TELIX’S THERAPEUTIC PROGRESS

Telix Pharmaceuticals (TLX)
Dr. Christian Behrenbruch, Chief Executive Officer
Dr. David Cade, Chief Business Officer

3:00PM

WRAP UP

James Unger, Head of Corporate Finance

For more information about the Bell Potter Healthcare Conference, go to our dedicated web page www.bellpotter.com.au/healthcare-conference-2020/

Disclaimer: Information relayed as part of the Conference is to be considered general investment advice only and does not constitute advice to any person. Although we believe that the advice and information which would be covered and/or provided as part of the Conference is reliable, Bell Potter Securities Limited has not independently verified information which is derived from publicly available sources, directors and management. As such, Bell Potter Securities Limited, its directors, employees and consultants do not represent, warrant or guarantee, expressly or impliedly, that the information that would be presented as part of the Conference is complete or accurate. Should you wish to consider and implement said information/advice, please assess the appropriateness of this information/advice with regard to your objectives, financial situation and needs, because the advice has not taken these factors into account. Bell Potter Securities Limited does not accept any responsibility to inform you of any matter that subsequently comes to its notice, which may affect any of the information presented to you as part of the Conference. Although we are elated to host you for another Conference, please note that you are not under any obligation to attend the Conference.